Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024

Kyverna Therapeutics, Inc.

Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.
Cash, equivalents and marketable securities $57.5M as of Dec 31, 2023; Feb 2024 IPO gross proceeds ~$366.9M.
Treated 14 autoimmune patients with KYV-101 CAR T therapy; FDA cleared Phase 2 trials in MS, MG and Phase 1/2 in systemic sclerosis.
Received FDA Fast Track Designations for KYV-101 in refractory MG, refractory progressive MS, and lupus nephritis.
Upcoming data releases at EULAR (Q2 2024), ECTRIMS (Q3 2024) and ACR (Q4 2024) for KYV-101.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kyverna Therapeutics, Inc. reported the full year ended December 31, 2023 results: net income net loss of $60.4 million, or a net loss per common share of $89.61, EPS net loss per common share of $89.61.

Period: the full year ended December 31, 2023
Net income: net loss of $60.4 million, or a net loss per common share of $89.61
EPS: net loss per common share of $89.61
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.